Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Budesonide study #6   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 24% Imp. Relative Risk, 95% CI ICU admission 22% Hospitalization 19% Strauss: Intranasal Corticosteroids Are Associated with Better Ou.. c19budesonide.com/strauss.html Favors budesonide Favors control
8/23 Prophylaxis study
Strauss et al., The Journal of Allergy and Clinical Immunology: In Practice, doi:10.1016/j.jaip.2021.08.007 (Peer Reviewed)
Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019
Source   PDF   Share   Tweet
Retrospective 72,147 COVID-19+ patients in the USA, showing lower mortality, ICU admission, and hospitalization with intranasal corticosteroid use.
risk of death, 23.5% lower, RR 0.76, p = 0.01, treatment 231 of 10,187 (2.3%), control 1,649 of 61,960 (2.7%), adjusted per study, odds ratio converted to relative risk, PSM.
risk of ICU admission, 22.3% lower, RR 0.78, p = 0.003, treatment 376 of 10,187 (3.7%), control 2,559 of 61,960 (4.1%), adjusted per study, odds ratio converted to relative risk, PSM.
risk of hospitalization, 18.9% lower, RR 0.81, p < 0.001, treatment 1,676 of 10,187 (16.5%), control 10,932 of 61,960 (17.6%), adjusted per study, odds ratio converted to relative risk, PSM.
Strauss et al., 8/23/2021, retrospective, USA, North America, peer-reviewed, 8 authors, 1 April, 2020 - 31 March, 2021.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical significance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit